Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?

R. Fleming, F. Broekmans, C. Calhaz-Jorge, L. Dracea, H. Alexander, A. Nyboe Andersen, C. Blockeel, J. Jenkins, B. Lunenfeld, P. Platteau, J. Smitz, D. De Ziegler

    Research output: Contribution to journalReview articlepeer-review

    50 Scopus citations


    The ability to predict the response potential of women to ovarian stimulation may allow the development of individualized ovarian stimulation protocols. This tailored approach to ovarian stimulation could reduce the incidence of ovarian hyperstimulation syndrome in women predicted to have an excessive response to stimulation or could improve pregnancy outcomes in women classed as poor responders. Namely, variation of the type of gonadotrophin-releasing hormone (GnRH) analogue or the form and dosage of gonadotrophin used for stimulation could be adjusted according to an individual's response potential. The serum concentration of anti-Müllerian hormone (AMH) is established as a reliable marker of ovarian reserve, with decreasing concentrations correlated with reduced response potential. This review examines the current evidence evaluating individualized ovarian stimulation protocols using AMH concentration as a predictive marker of ovarian response. The rationale behind why specific treatment protocols based on individual response potential may be more suitable is also discussed. Based on current evidence, it appears that the use of AMH serum concentrations to predict ovarian response and optimize treatment strategies is a promising approach for improving pregnancy outcomes in women undergoing ovarian stimulation. However, prospective randomized controlled trials evaluating this approach are needed before any firm conclusions can be drawn.

    Original languageEnglish
    Pages (from-to)431-439
    Number of pages9
    JournalReproductive BioMedicine Online
    Issue number5
    StatePublished - 2013

    Bibliographical note

    Funding Information:
    Medical writing support for this article was provided by Farah Dalwai, Medicus International and was funded by an unrestricted grant from Ferring Pharmaceuticals, St Prex, Switzerland.


    • GnRH agonist
    • GnRH antagonist
    • anti-Müllerian hormone (AMH)
    • gonadotrophin-releasing hormone
    • ovarian response
    • ovarian stimulation


    Dive into the research topics of 'Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?'. Together they form a unique fingerprint.

    Cite this